The abstract is read at the publisher; the summary is JClub's.
VSP-51-2, a dual-action small molecule in preclinical PCOS models, restores regular estrous cyclicity and improves insulin sensitivity while suppressing hyperandrogenism without significantly perturbing measured HPO hormones.
- Why it matters: PCOS therapies often miss both metabolic insulin resistance and reproductive hyperandrogenism, leaving a need for a single strategy that can address both core pathologies together.
- What they did: The compound was engineered as a selective PPARγ modulator but shows potent uncompetitive inhibition of AKR1C3 via a putative allosteric mechanism; in PCOS models it was tested for estrous cycling, ovarian morphology, insulin sensitivity, and androgen-related outcomes.
- The result: VSP-51-2 blocks PPARγ phosphorylation at Ser 273 to enhance adiponectin secretion and GLUT4-mediated glucose uptake, and it is predicted to constrain AKR1C3 androgen biosynthesis, supporting dual-target preclinical proof-of-concept.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.